MDMA and MDXXF Related Headlines
Go Back- PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100
- Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
- PharmAla Biotech forms joint venture for APA-01 drug development
- PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
- PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
- PharmAla Issues Q2 Financial Statements and Grants Options
- Cortexa Advances Commercialisation of MDMA Supply in Australia
- PharmAla signs supply deal with Nautilus Sanctuary for phase 2 MDMA trial
- PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Resp
- PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia
- PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data
- PharmAla appoints Lennie Ryer to board, accepts Slassi resignation
- PharmAla Announces Changes to Board of Directors
- PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements
- PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules
- PharmAla Files Final Base Shelf Prospectus and Signs Term Sheet with Radium Capital
- PharmAla Launches Nexus Portal for MDMA Prescribers and Therapists
- PharmAla Partners with Veridion Group as Exclusive Distributor in New Zealand
- PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus
- PharmAla Completes Import of LaNeo MDMA for US Distribution
- PharmAla Incorporates Australian Entity for Clinical Research
- PharmAla Delivers MDMA to Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License
- PharmAla Issues Q3 Financial Statements
MDMA and MDXXF Related Press Releases
Go Back- PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100
- Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
- PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
- PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
- PharmAla Issues Q2 Financial Statements and Grants Options
- Cortexa Advances Commercialisation of MDMA Supply in Australia
- PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Resp
- PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia
- PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data
- PharmAla Announces Changes to Board of Directors
- PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements
- PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules
- PharmAla Files Final Base Shelf Prospectus and Signs Term Sheet with Radium Capital
- PharmAla Launches Nexus Portal for MDMA Prescribers and Therapists
- PharmAla Partners with Veridion Group as Exclusive Distributor in New Zealand
- PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus
- PharmAla Completes Import of LaNeo MDMA for US Distribution
- PharmAla Incorporates Australian Entity for Clinical Research
- PharmAla Delivers MDMA to Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License
- PharmAla Issues Q3 Financial Statements
